Navigation Links
Sigma® Life Science Launches Genetically Modified Human Cell Lines for Breast Cancer Research

ST. LOUIS, July 22, 2011 /PRNewswire/ -- Sigma Life Science, the innovative biological products and services research business of Sigma-Aldrich® (Nasdaq: SIAL), today announced the expansion of its CompoZr® Oncology Disease Model portfolio with the release of the first in its collection of breast cancer-specific knockout and knockin cell lines for drug discovery and research. These modified epithelial cell lines are expected to provide researchers with a characterized and known genetic background for basic research and pathway analysis. They are supplied with isogenic parental cell lines to allow high throughput, cell-based screening for drug discovery, target validation and mechanistic studies. For more information, visit

Important breast cancer genes – such as Estrogen Receptor, PTEN and HER2 – have been targeted using Sigma Life Science's proprietary Zinc Finger Nuclease (ZFN) technology, to create stable and heritable genomic knockouts and to provide new cellular models of cancer. These modified human epithelial cell lines, including MCF10A, among others, offer researchers the complete knockout of disease-relevant target gene expression.

Supriya Shivakumar, Global Marketing Manager at Sigma Life Science, said, "These new knockout breast cancer cell lines, created using Sigma's ground-breaking CompoZr® ZFN technology, are expected to be ideal for high throughput screens to determine whether patient-relevant genetic alterations affect drug sensitivity or drug resistance. Researchers now have immediate access to high-quality knockout isogenic human cell lines, which should reduce the costs and labor required for basic research and drug discovery, and could accelerate the development of personalized medicine."

Cautionary statement: The foregoing release contains forward-looking statements that can be identified by terminology such as "expected," "offers," "can," "should" or similar expressions, or by expressed or implied discussions regarding potential future revenues from products derived therefrom. You should not place undue reliance on these statements. Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that the CompoZr Oncology Disease Model products described herein will assist the Company to achieve any particular levels of revenue in the future. In particular, management's expectations regarding products associated with CompoZr Oncology Disease Model products could be affected by, among other things, unexpected regulatory actions or delays or government regulation generally; the Company's ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry and general public pricing pressures; the impact that the foregoing factors could have on the values attributed to the Company's assets and liabilities as recorded in its consolidated balance sheet, and other risks and factors referred to in Sigma-Aldrich's current Form 10-K on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Sigma-Aldrich is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Sigma Life Science: Sigma Life Science is a Sigma-Aldrich business that represents the Company's leadership in innovative biological products and services for the global life science market and offers an array of biologically-rich products and reagents that researchers use in scientific investigation. Product areas include biomolecules, genomics and functional genomics, cells and cell-based assays, transgenics, protein assays, stem cell research, epigenetics and custom services/oligonucleotides. Sigma Life Science also provides an extensive range critical bioessentials like biochemicals, antibiotics, buffers, carbohydrates, enzymes, forensic tools, hematology and histology, nucleotides, amino acids and their derivatives, and cell culture media.

About Sigma-Aldrich: Sigma-Aldrich is a leading Life Science and High Technology company committed to Enabling Science to Improve the Quality of Life. Its chemical and biochemical products and kits are used in scientific research, including genomic and proteomic research, biotechnology, pharmaceutical development and as key components in pharmaceutical, diagnostic and other high technology manufacturing. The Company has customers in life science companies, university and government institutions, hospitals, and in industry. Over one million scientists and technologists use its products. Sigma-Aldrich operates in 40 countries and has 8,000 employees providing excellent service worldwide. For more information about Sigma-Aldrich, please visit its award-winning Web site at

Sigma-Aldrich, Sigma and CompoZr are registered trademarks of Sigma-Aldrich Co. LLC.

SOURCE Sigma-Aldrich
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Sigma® Life Science Enters Genetically Modified Cell Market
2. Sigma® Life Science Awarded Silver in Top Ten Innovations 2010
3. Sigma® Life Science Creates Worlds First Knock-in Rats using Zinc Finger Nuclease Technology
4. Sigma® Life Science Launches Pre-designed CompoZr® Knockout Zinc Finger Nucleases for Entire Human Genome
5. Sigma® Life Science Launches Suite of Knockout Rats to Model Parkinsons Disease
6. Sigma® Life Science Joins AMDeCs Vendor Partnership Program, Further Enhancing Value to Academic Medical Research Centers
7. Sigma® Life Science and Kraig Biocraft Laboratories to Develop Silkworms for the Production of Spider Silk
8. Sigma® Life Science and Kings College London Co-Developing miRNA Target Identification Technology
9. The Science of Music Meets the Art of Medicine - ARIMM 3rd Annual Conference at IPFW, September 12-13, 2008
10. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2008
11. Carna Biosciences Signs Reagent Supply Agreement with Caliper Life Sciences
Post Your Comments:
(Date:11/30/2015)...  Northwest Biotherapeutics (NASDAQ: NWBO ) ("NW Bio"), ... for solid tumor cancers, announced today that the Board ... the Company welcomes Neil Woodford,s call for ... internet report on NW Bio.  The Company,s Board is ... stated, "We agree with Mr. Woodford that, at ...
(Date:11/30/2015)... , ... November 30, 2015 ... ... today announced tighter software integration with MarkLogic, the Enterprise NoSQL database platform ... information to drive change. , Smartlogic’s Content Intelligence capabilities provide a robust ...
(Date:11/30/2015)... N.J. and PETACH TIKVAH, Israel ... (NASDAQ: BCLI ), a leading developer of adult ... wholly-owned subsidiary, Brainstorm Cell Therapeutics Ltd., has been awarded an ... Office of the Chief Scientist (OCS). This grant, the ... Brainstorm for 2015 activities to approximately $1.8 million (approximately NIS7 ...
(Date:11/28/2015)... ... 28, 2015 , ... • Jeon Jin Bio Corp, a Korean Biotech venture ... , Bird Free, an oil-based, gel formula ... modalities including visual, smell, taste and touch, enabling safe, effective avian control without toxic ...
Breaking Biology Technology:
(Date:11/26/2015)... 2015 Research and Markets ( ) ... Sensors - Technology and Patent Infringement Risk Analysis" ... --> Fingerprint sensors using capacitive technology ... fingerprint sensor vendor Idex forecasts an increase of 360% ... devices and of the fingerprint sensor market between 2014 ...
(Date:11/20/2015)... 20, 2015 NXTD ) ("NXT-ID" ... the growing mobile commerce market and creator of the ... , was recently interviewed on The RedChip Money ... this weekend on Bloomberg Europe , Bloomberg Asia, ... --> NXTD ) ("NXT-ID" or the "Company"), a ...
(Date:11/19/2015)... , Nov. 19, 2015  Based on its in-depth ... Sullivan recognizes BIO-key with the 2015 Global Frost & ... Frost & Sullivan presents this award to the company ... to the needs of the market it serves. The ... meets and expands on customer base demands, the overall ...
Breaking Biology News(10 mins):